ArticleInfection and drug resistance2021
High Prevalence of
Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Definitional ambiguity and the dual threat of Hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis.Infection · 2026Pooled it
- Carbapenem-resistant Enterobacteriaceae in the livestock, humans and environmental samples around the globe: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Prevalence, Virulence, and Pathogenic Mechanisms of Mastitis-AssociatedVeterinary sciences · 2026Review
- Prevalence, Risk Factors, and Clinical Outcomes of HypervirulentIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Distribution Features and Antimicrobial Resistance Trends of Clinical Pathogens: A Retrospective Study in a Tertiary Teaching Hospital in East China (2020-2024).Infection and drug resistance · 2025Article
- Discovery of clinical isolation of drug-resistantMicrobiology spectrum · 2024Article
- Occurrence of carbapenem-resistant hypervirulent Klebsiella pneumoniae in oysters in Egypt: a significant public health issue.Annals of clinical microbiology and antimicrobials · 2024Article
- HypervirulentFrontiers in microbiology · 2024Article
- Gallium Nitrate Enhances Antimicrobial Activity of Colistin against Klebsiella pneumoniae by Inducing Reactive Oxygen Species Accumulation.Microbiology spectrum · 2023Article
- Epidemiological characteristics and molecular evolution mechanisms of carbapenem-resistant hypervirulentFrontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPURPOSE: To show the high prevalence of HvKP infections regarding clinical characteristics and antimicrobial resistance in Anhui province. PATIENTS AND
methodsA retrospective analysis was conducted to study the clinical data of 115 strains of
resultsOverall, 59.1% (68/115) cases were HvKP infections, mainly from the department of intensive care unit (ICU, n=14, 20.6%) and the department of respiratory and critical care (n=13, 19.1%). K2 was the most prevalent capsular serotype (n=26), followed by K1 (n=21). The results of MLST identification of 68 strains showed that ST23 (n=15, 22.1%) was the most common type of ST, followed by ST11 and ST65 (n=12, 17.6%), ST86 (n=9, 13.2%), and ST412 (n=6, 8.8%). Among 68 hvKP strains, 12 isolates were carbapenem resistant, and all except two harboured
conclusionThe high incidence of carbapenemase producing HvKP in the Anhui province, especially the higher mortality of HvKP, should be paid more attention. Meanwhile, epidemiological surveillance and clinical treatment strategies should be continuously determined and implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.